Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic Cation transporter 1

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1780-1784

  William Higgins, J ^a   Ke, Alice B ^a   Zamek Gliszczynski, Maciej J ^b  

^a CERTARA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BROMSULFOPHTHALEIN; CHOLECYSTOKININ OCTAPEPTIDE; CLARITHROMYCIN; ESTRONE SULFATE; HYDROXYITRACONAZOLE; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1A; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2B1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; TAUROCHOLIC ACID; TETRYLAMMONIUM; UNCLASSIFIED DRUG; CYTOCHROME P450 3A INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; EMBRYO; FEMALE; GENE CLUSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; KNOCKOUT MOUSE; LIVER; METABOLISM;

ANIMALS; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A INHIBITORS; ITRACONAZOLE; KETOCONAZOLE; LIVER; MALE; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORTER 1;

EID: 84907476662     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058784     Document Type: Article

References (22)

1. Clarysse S, Psachoulias D, Brouwers J, Tack J, Annaert P, Duchateau G, Reppas C, and Augustijns P (2009) Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 26:1456-1466.
2. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
3. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, and Perry WL, 3rd (2003) Cloning and functional characterization of the multidrug resistance-Associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther 2:307-316.
4. Han B, Mao J, Chien JY, and Hall SD (2013) Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 41:1329-1338.
5. Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, and Zamek-Gliszczynski MJ (2014) Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATPmediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos 42:182-192.
6. Higgins JW, Bedwell DW, and Zamek-Gliszczynski MJ (2012) Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 40:1170-1177.
7. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
8. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, and Sugiyama Y (2013) Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17b-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos 41:1859-1866.
9. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94: 1140-1146.
10. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
11. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, and Hall SD (2014) Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther 95: 473-476.
12. Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, and Wilkinson GR (1999) Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther 291:1204-1209.
13. Liu L and Unadkat JD (2013) Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs. Biopharm Drug Dispos 34:155-164.
14. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90: 575-581.
15. Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel KD, Burhenne J, Weiss J, Mikus G, and Haefeli WE (2014) Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. Br J Clin Pharmacol 77:141-148.
16. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, and Tsuji A (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34: 1423-1431.
17. Smith DA, Di L, and Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929-939.
18. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2010) Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88:499-505.
19. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77-85.
20. Yabe Y, Galetin A, and Houston JB (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808-1814.
21. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transportmediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.
22. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, and Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351-359.